TFB Advisors LLC Decreases Position in Merck & Co., Inc. $MRK

TFB Advisors LLC decreased its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 6.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,810 shares of the company’s stock after selling 242 shares during the quarter. TFB Advisors LLC’s holdings in Merck & Co., Inc. were worth $302,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in MRK. Legend Financial Advisors Inc. acquired a new position in Merck & Co., Inc. during the second quarter worth approximately $25,000. Barnes Dennig Private Wealth Management LLC acquired a new position in Merck & Co., Inc. during the first quarter worth approximately $27,000. CBIZ Investment Advisory Services LLC increased its position in Merck & Co., Inc. by 141.7% during the first quarter. CBIZ Investment Advisory Services LLC now owns 377 shares of the company’s stock worth $34,000 after buying an additional 221 shares during the period. MorganRosel Wealth Management LLC acquired a new position in Merck & Co., Inc. during the first quarter worth approximately $36,000. Finally, Advantage Trust Co increased its position in Merck & Co., Inc. by 57.1% during the second quarter. Advantage Trust Co now owns 550 shares of the company’s stock worth $44,000 after buying an additional 200 shares during the period. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Wall Street Analyst Weigh In

MRK has been the topic of several research analyst reports. Berenberg Bank lowered Merck & Co., Inc. from a “buy” rating to a “hold” rating and cut their price target for the stock from $100.00 to $90.00 in a research report on Wednesday, September 17th. Morgan Stanley cut their price target on Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating on the stock in a research report on Thursday, July 10th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Merck & Co., Inc. in a research report on Wednesday, October 8th. Wells Fargo & Company cut their price target on Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 30th. Finally, Citigroup initiated coverage on Merck & Co., Inc. in a research report on Monday, October 13th. They set a “neutral” rating and a $95.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $104.33.

Merck & Co., Inc. Trading Down 0.0%

NYSE:MRK opened at $87.60 on Thursday. The firm has a market cap of $218.81 billion, a P/E ratio of 13.50, a PEG ratio of 0.96 and a beta of 0.37. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt-to-equity ratio of 0.69. The stock’s 50 day simple moving average is $84.28 and its 200-day simple moving average is $81.43. Merck & Co., Inc. has a 12-month low of $73.31 and a 12-month high of $107.36.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Tuesday, July 29th. The company reported $2.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.03 by $0.10. The business had revenue of $15.81 billion for the quarter, compared to analyst estimates of $15.92 billion. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. Equities analysts anticipate that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.